Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Ambulatory, postmenopausal Japanese women with osteoporosis (defined as bone mineral density T-score of ≤ -4.00 at the lumbar spine or BMD T-score of ≤ -3.50 at the total hip, or femoral neck)~Exclusion Criteria:~* Severe osteoporosis~* Use of agents affecting bone metabolism~* History of metabolic or bone disease (except osteoporosis)~* Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)~* Current hyper- or hypocalcemia~* Current, uncontrolled hyper- or hypothyroidism~* Current, uncontrolled hyper- or hypoparathyroidism

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
- Romosozumab 70 mg (Type: EXPERIMENTAL): Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
- Romosozumab 140 mg (Type: EXPERIMENTAL): Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
- Romosozumab 210 mg (Type: EXPERIMENTAL): Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).